InvestorsHub Logo
Post# of 175024
Next 10
Followers 19
Posts 1800
Boards Moderated 0
Alias Born 01/21/2018

Re: None

Tuesday, 06/07/2022 9:14:18 AM

Tuesday, June 07, 2022 9:14:18 AM

Post# of 175024
One investors opinion.

We have 6 months of cash which takes us to the end of the year. This is enough time to get the IDE done.

Q3 becomes the IDE quarter. July the FDA approved the last pre IDE animal test plan and RDGL with Johns Hopkins help initiate the test all in July.

Animal test doesn't take long and test is completed and written up before the end of August.

Official IDE is submitted by Sept and approved for Human trials by October.

Q4 things really get interesting. Someone or some entity will want all they can get from the company and the offering closes quickly and the market cap moves to $200M, maybe $250M. Let's call it a $0.50 share price with now 400M shares. Someone may want to buy RDGL at the cheap at $500M and the good doctor and chairman will have a tough call to make because at $500M you have to consider current shareholder value. $1.25 share price by end of year when it now sits at $0.08 is a price the BOD has to seriously consider. I would vote yes.

All my opinion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News